CN100556894C - 1H-imdazole derivatives as Cannibinoid receptor modulators - Google Patents
1H-imdazole derivatives as Cannibinoid receptor modulators Download PDFInfo
- Publication number
- CN100556894C CN100556894C CNB2004800243493A CN200480024349A CN100556894C CN 100556894 C CN100556894 C CN 100556894C CN B2004800243493 A CNB2004800243493 A CN B2004800243493A CN 200480024349 A CN200480024349 A CN 200480024349A CN 100556894 C CN100556894 C CN 100556894C
- Authority
- CN
- China
- Prior art keywords
- compound
- phenyl
- group
- alkyl
- imidazoles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The present invention relates to one group of 1H-imdazole derivatives as Cannibinoid receptor modulators, the method for preparing these compounds, the new intermediate product that is used for synthetic this imdazole derivatives, the method for preparing these intermediate products, contain the pharmaceutical composition of one or more these 1H-imdazole derivatives, and these pharmaceutical compositions are used for the treatment of the mental disorder that relates to Cannabined receptor and the application of neurological disorder as activeconstituents.Described compound has general formula (I), wherein R, R
1-R
4Has the implication that in specification sheets, provides with X.
Description
The present invention relates to one group of 1H-imdazole derivatives as cannaboid (cannabinoid) receptor modulators, the method for preparing these compounds, the new intermediate product that is used for synthetic described imdazole derivatives, the method for preparing these intermediate products, contain the pharmaceutical composition of one or more these 1H-imdazole derivatives, and these pharmaceutical compositions are used for the treatment of the mental disorder that relates to Cannabined receptor and the application of neurological disorder as activeconstituents.
The invention still further relates to the application that compound disclosed herein is used to prepare the medicine that beneficial effect is provided.This open beneficial effect or those skilled in the art according to specification sheets and general knowledge known in this field this beneficial effect as can be seen.The invention still further relates to the application that compound of the present invention is used to prepare treatment or preventing disease or illness.More specifically, the present invention relates to a kind of new application for the treatment of disclosed herein or those skilled in the art according to specification sheets and conspicuous disease of general knowledge known in this field or illness.In embodiments of the invention, compound disclosed herein is used to prepare medicine.
According to the known 1H-imdazole derivatives of WO03/027076 as CB
1Receptor modulators.But, the feature of the compound described in the WO03/027076 be water-soluble a little less than.Target of the present invention is to improve the water-soluble of 1H-imdazole derivatives, keeps their Cannabined receptor to regulate active simultaneously.According to prior art, how to realize that this target is not apparent.
Surprisingly, find in the 1H-imidazole nucleus, to introduce the 5-amino methyl and caused water-soluble increase.And the derivative that comprises this 5-amino methyl part keeps their Cannabined receptor to regulate activity, for example receptor antagonism, receptor inverse agonism or acceptor (part) agonism.
The present invention relates to acceptable salt and prodrug on the compound of general formula (I) and the pharmacology thereof:
Wherein:
-R and R
1Identical or different and represent phenyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl or triazinyl; described group can be replaced by 1,2,3 or 4 substituting group Y; described substituting group can be selected from methyl, ethyl, propyl group, methoxyl group, oxyethyl group, hydroxyl, hydroxymethyl, hydroxyethyl, chlorine, iodine, bromine, fluorine, trifluoromethyl, trifluoromethoxy, methyl sulphonyl, phenyl and cyano group identical or differently; perhaps R represents naphthyl
Perhaps R represents C
1-8Branched-chain or straight-chain alkyl, C
3-7Cycloalkyl, C
3-7Cycloalkyl-C
1-2Alkyl, C
3-8Side chain or straight chain mix alkyl, C
5-7Heterocyclylalkyl or C
5-7Heterocyclylalkyl-C
1-2Alkyl, described group can be by fluorine atom or CF
3Or the replacement of OH group,
-R
2And R
3Identical or different, and represent H, C
1-5Branched-chain or straight-chain alkyl, described alkyl can be replaced by hydroxyl or 1-3 fluorine atom, perhaps
R
2Represent side chain or straight chain C
1-3Alkoxyl group, condition are R
3Represent H or methyl, perhaps
-R
2And R
3Form the heterocyclic group of saturated or unsaturated non-fragrance, monocycle or dicyclo with their bonded nitrogen-atoms with 5-10 annular atoms, described heterocyclic group comprises one or two ring hetero atom that is selected from group (N, O, S), described heteroatoms can be identical or different, and described heterocyclic group can be by C
1-3Alkyl, hydroxyl or fluorine atom replace,
-R
4Represent H or methyl, ethyl, propyl group, sec.-propyl or normal-butyl,
-X represents subgroup (i) or one of (ii),
Wherein:
-R
5Represent hydrogen atom or C
1-8Branched-chain or straight-chain alkyl, C
1-3-alkyl-SO
2-C
1-4-alkyl, C
3-7Cycloalkyl, C
3-7-cycloalkyl-C
1-2-alkyl, C
5-7-Heterocyclylalkyl-C
1-2-alkyl, described group can be replaced by hydroxyl, methyl or trifluoromethyl or fluorine atom, and described C
5-7-Heterocyclylalkyl-C
1-2-alkyl comprises one or two heteroatoms that is selected from group (O, N, S), perhaps R
5Represent phenyl, benzyl, styroyl or phenyl propyl, described group can be replaced by 1-3 substituting group Y on its phenyl ring, and wherein Y has above-mentioned implication, perhaps R
5Represent pyridyl or thienyl,
-R
6Represent hydrogen atom or side chain or straight chain C
1-3Alkyl,
-R
7Represent hydrogen, side chain or straight chain C
1-8Alkyl or C
3-8-cycloalkyl-C
1-2-alkyl, side chain or straight chain C
1-8Alkoxyl group, C
3-8Cycloalkyl, C
5-10Bicyclic alkyl, C
5-10Bicyclic alkyl-C
1-2Alkyl, C
6-10Tricyclic alkyl, C
6-10Tricyclic alkyl methyl, described group can comprise one or more heteroatomss from group (O, N, S), and described group can be by hydroxyl, a 1-3 methyl, ethyl or 1-3 fluorine atom replacement, perhaps R
7Represent phenyl, phenyl amino, phenoxy group, benzyl, styroyl or phenyl propyl, the phenyl ring of choosing wantonly at them is replaced by 1-3 substituting group Y, and wherein Y has above-mentioned implication, perhaps R
7Represent pyridyl or thienyl, perhaps R
7Represent group NR
8R
9, wherein
R
8And R
9Form saturated or unsaturated, the monocycle with 4-10 annular atoms or the heterocyclic group of dicyclo with their bonded nitrogen-atoms, described heterocyclic group comprises one or more heteroatomss from group (O, N, S), and described heterocyclic group can be by side chain or straight chain C
1-3Alkyl, phenyl, hydroxyl or trifluoromethyl or fluorine atom replace, perhaps
R
6And R
7Form saturated or unsaturated, the monocycle with 4-10 annular atoms or the heterocyclic group of dicyclo with their bonded nitrogen-atoms, described heterocyclic group comprises one or more heteroatomss that are selected from group (O, N, S), and described heterocyclic group can be by side chain or straight chain C
1-3Alkyl, phenyl, amino, hydroxyl or trifluoromethyl or fluorine atom replace.
All compound, racemic modification, non-enantiomer mixture and independent steric isomers with formula (I) belong to the present invention.Therefore the substituting group on the potential unsymmetrical carbon is that the compound of R configuration or S configuration belongs to the present invention.
Prodrug is itself not have activity but the therapeutical agent that changes into one or more active metabolites.Prodrug is the biological reversible derivatization thing that is used to overcome some barrier that utilizes the parent drug molecule.These obstacles include but not limited to solubleness, perviousness, stability, the metabolism of preceding system and target restriction (Medicinal Chemistry:Principles and Practice, 1994, ISBN0-85186-494-5, Ed.:F.D.King, p.215; J.Stella, " Prodrugs astherapeutics ",
Expert Opin.Ther.Patents, 14(3) 277-280,2004; People such as P.Ettmayer, " Lessons learned from marketed andinvestigational prodrugs ", J.Med.Chem., 47,2393-2404,2004).Prodrug promptly has formula the compound of compound of (I) belongs to the present invention being metabolized to during to people's administration by any known approach.Particularly the present invention relates to have the compound of uncle or secondary amino group or hydroxyl.These compounds can with organic acid reaction obtain the having formula compound of (I), wherein exist in other group of removing easily after the administration, such as but not limited to amidine, enamine, Mannich (Mannich) alkali, hydroxyl-methylene derivatives, O-(acyloxy-methene amido manthanoate) derivative, carbamate, ester, acid amides or enamine ketone (enaminone).
The present invention is specifically related to the to have formula compound of (I), wherein X represents subgroup (ii), and all other symbols have above-mentioned implication.
More specifically; the present invention relates to the compound of formula (I); wherein X represents subgroup (ii); and R represents phenyl; thienyl; pyridyl; pyrimidyl; pyrazinyl; pyridazinyl or triazinyl; described group can be by 1; 2; 3 or 4 substituting group Y replace; described substituting group can be selected from methyl identical or differently; ethyl; propyl group; methoxyl group; oxyethyl group; hydroxyl; hydroxymethyl; hydroxyethyl; chlorine; iodine; bromine; fluorine; trifluoromethyl; trifluoromethoxy; methyl sulphonyl; phenyl or cyano group; perhaps R represents naphthyl, and other all symbols has above-mentioned implication.
The general aspect of synthetic
The compound of formula (I) and formula (II) and synthetic mesophase product (VI) can prepare by diverse ways respectively.WO 03/027076 and WO 03/063781 have described the synthetic of imidazoles relevant on the structure as Cannibinoid receptor modulators.WO 03/040107 also discloses synthesizing as imidazoles relevant on the structure of anti-obesity compound.The factors such as final structure feature that exist as in the compatibility of functional group and agents useful for same, the possibility, catalyzer, activation and the coupling reagent that use protecting group and the prepared final compound are depended in the selection of ad hoc approach.Can see about amine to the activation of carboxylic acid and the more information of couling process:
a)M.Bodanszky and A.Bodanszky：The Practice of PeptideSynthesis，Springer-Verlag，New York，1994；ISBN：0-387-57505-7；
b)K.Akaji et al，Tetrahedron LetL，1994，35，3315-3318)；
c)F.Albericio et al.，Tefrahedron Lett.，1997，38，4853-4856)。
About trimethyl aluminium Al (CH
3)
3The more information of the amidate action of promoted ester is found in: J.I.Levin, and E.Turos, S.M.Weinreb, Synth Commun.1982,12,989-993.).More information about nucleophilic reagent, electrophilic reagent and leavings group notion is seen: M.B.Smith and J.March:Advanced organic chemistry, p.275,5
ThEd. (2001) John Wiley ﹠amp; Sons, New York, ISBN:0-471-58589-0).Be found in about the adding of protecting group in the organic synthesis and the more information of removing subsequently: T.W.Greene and P.G.M.Wuts, " Protective Groups in Organic Synthesis ", third edition, John Wiley ﹠amp; Sons, Inc., New York, 1999.
Suitable synthetic method of the present invention is as follows:
Synthetic route A
Make the have formula compound of (II)
Wherein R, R
1, R
4Have above-mentioned implication, and R
10Represent branched-chain or straight-chain alkyl (C
1-4) or benzyl
With regioselectivity brominated compound such as N-bromosuccinimide (NBS), at organic solvent such as CCl
4In, reaction can obtain the compound of formula (III) in the presence of free-radical initiator such as dibenzoyl superoxide
R wherein, R
1, R
4And R
10Has above-mentioned implication.Compound and general formula R with formula (III)
2R
3The amine reaction of NH can obtain the compound of general formula (IV)
Wherein R, R
1, R
2, R
3, R
4And R
10Has above-mentioned implication.
According to the described similar method of WO03/027076, the compound of the general formula (IV) that obtained according to synthetic route A can be changed into the compound of general formula (I), wherein X represents subgroup (ii).
Synthetic route B
Make the have formula compound of (IV), wherein R, R
1, R
2, R
3And R
4Has above-mentioned implication and R
10Represent hydrogen atom
With N-methoxyl group-N-methylamine reaction, can obtain the compound of formula V,
Wherein R, R
1, R
2, R
3And R
4Has above-mentioned implication.Compound and general formula R with formula V
5-MgBr (Grignard reagent) or R
5The organometallic compound of-Li (organolithium reagent) reacts, and can obtain the compound of general formula (I), and wherein X represents subgroup (i).This reaction is preferably at N
2In anhydrous inert organic solvent, finish under the atmosphere.
Synthetic route C
Can be according to Tetrahedron Lett (1971), 18, the described method of 1439-1440 (Heindel and Chun) obtains 2-aryl-(1H)-imidazoles-4-manthanoate.Then suitable imidazoles N-atom derivatize (for example N-arylation or N-alkylated reaction) can be produced the compound with formula (VI).Make the have formula compound of (VI)
Wherein R and R
1Have above-mentioned implication, and R
10Represent branched-chain or straight-chain alkyl (C
1-4) or benzyl,
With non-nucleophilic base such as diisopropylaminoethyl lithium (LDA), react in inert water-free organic solvent such as THF with electrophilic reagent such as ethyl formate then, can obtain the compound of general formula (VII)
R in this synthetic route wherein, R
1, R
4And R
10Has above-mentioned implication.At reductive agent such as NaCNBH
3Use general formula R under existing
2R
3The amine of NH will have the compound reduction amination of general formula (VII), can obtain the compound of general formula (IV)
Wherein R, R in this reaction scheme
1, R
2, R
3, R
4And R
10Has above-mentioned implication.
According to the described similar method of WO03/027076, the compound of the general formula (IV) that obtained according to synthetic route C can be changed into the compound of general formula (I), wherein X represents subgroup (ii).
Pharmacy acceptable salt can use routine techniques as known in the art, for example by for example mineral acid example hydrochloric acid or organic acid mix and obtain with compound of the present invention and suitable acid.
Because their Cannabined receptor is regulated active, compound of the present invention is applicable to the treatment psychotic disorder, psychosis for example, anxiety, depressed, attention deficit, dysmnesia, cognitive disorder, abnormal food appetite, fat, fat and the drug-induced obesity of teenager particularly, habituation, desire, drug dependence, and neuropathy, neurodegenerative disease for example, dull-witted, muscular tension is not normal, muscle rigidity, tremble, epilepsy, multiple sclerosis, traumatic brain injury, apoplexy, Parkinson's disease, Alzheimer, epilepsy, Huntington, Tourette's syndrome, cerebral ischemia, cerebral crisis, craniocerebral trauma, apoplexy, Spinal injury, the neuritis disease, the spot sclerosis, viral encephalitis, the demyelination relative disease, and be used for the treatment of the pain disease, comprise that Algopsychalia disease and other relate to the disease of cannaboid neurotransmission, comprise the treatment septic shock, glaucoma, cancer, diabetes, vomiting, feel sick, asthma, respiratory tract disease, gastrointestinal illness, sexual dysfunction, liver cirrhosis, stomach ulcer, diarrhoea and cardiovascular disorder.
The Cannabined receptor of The compounds of this invention is regulated active when uniting use with lipase inhibitor, is particularly useful for treating obesity, teenager's obesity and drug-induced obesity.The specific examples for compounds that can be used for this combination preparation is (but being not limited to) synthetic fat enzyme inhibitors orlistat, isolating lipase inhibitor such as mud are moored Si Tating (lipstatin) (from poison three plain streptomycetes) from the microorganism, the Ai Bo Lars leads to B (ebelactone B) (from the A Bula streptomycete), the synthesis of derivatives of these compounds and known plant milk extract with lipase inhibiting activity, for example extract of Rhizoma Alpiniae Officinarum (Alpinia officinarum) or from then on isolated compound such as 3-methyl ethergalangin (from kaempferia galamga (A.officinarum)) in the extract.
Can use subsidiary material and/or liquid or solid solid support material compound of the present invention to be transformed into the form that is suitable for by the ordinary method administration.
The compounds of this invention is generally as the pharmaceutical composition administration, and they are owing to these compounds, more specifically the existence for specific compound disclosed herein becomes important and new embodiment of the present invention.The type of operable pharmaceutical composition includes but not limited to other type that tablet, chewable tablet, capsule, solution, parenteral solution, suppository, suspension and disclosed herein or those skilled in the art know according to specification sheets and general knowledge known in this field.In embodiments of the invention, provide a kind of drug packages or test kit that comprises the composition of one or more pharmaceutical compositions of the present invention.Relevant with these containers is various written materials, the notice of government organs' prescribed form of production, use or the sale of operation instruction or management medicine for example, and described notice shows by the mechanism of this productions, uses or sale ratifies to be used for people or beastly administration.
Pharmacological method
Cannaboid CB
1The external avidity of acceptor
The compounds of this invention is to cannaboid CB
1The avidity of acceptor can use the membrane product of Chinese hamster ovary (CHO) cell to measure, wherein with people's cannaboid CB
1Acceptor with as radioligand [
3H] CP-55,940 transfections stably together.With the cytolemma goods of prepared fresh with [
3H]-after part cultivates under the situation that adds or do not add The compounds of this invention, by with glass fibre filtering separation combination and free part.Measure the radioactivity of strainer by liquid scintillation counting(LSC).
Cannaboid CB
2The external avidity of acceptor
The compounds of this invention is to cannaboid CB
2The avidity of acceptor can use the membrane product of Chinese hamster ovary (CHO) cell to measure, wherein with people's cannaboid CB
2Acceptor with as radioligand [
3H] CP-55,940 transfections stably together.With the cytolemma goods of prepared fresh with [
3H]-after part cultivates under the situation that adds or do not add The compounds of this invention, by with glass fibre filtering separation combination and free part.Measure the radioactivity of strainer by liquid scintillation counting(LSC).
Cannaboid CB
1The external antagonistic action of acceptor
CB
1The external antagonistic action of acceptor can be used the CB that clones in Chinese hamster ovary (CHO) cell
1Acceptor is estimated.Chinese hamster ovary celI growth in being supplemented with the Dulbecco improvement Eagle substratum (DMEM) of 10% heat inactivation fetal bovine serum.The suction substratum also replaces with DMEM, and described substratum does not contain fetal bovine serum, but comprise [
3H]-arachidonic acid, and at cell cultures stove (5%CO
2/ 95% air; 37 ℃; Water saturated atmosphere) overnight incubation in.To during this period, [
3H]-arachidonic acid introducing membrane phospholipid.In test day, extract substratum out also with the 0.5mL DMEM washing that comprises 0.2% fetal bovine serum (BSA) three times.Use WIN55,212-2 stimulates CB
1Acceptor causes activating PLA
2, incite somebody to action then [
3H]-arachidonic acid is released into substratum.This WIN 55,212-2 inductive discharge the mode that relies on concentration by CB
1The receptor antagonist antagonism.
Cannaboid CB
1Antagonistic action in the body of acceptor
CB
1Antagonistic action can be used CP-55 in the body of acceptor, and 940 inductive hypotention in rats are tested and estimated.With the male normotensive rat (225-300g of Sodital (80mg/kg ip) anesthesia; Harlan, Horst, The Netherlands).By being inserted to the sleeve pipe of left neck artery, adopt Spectramed DTX-plus pressure transmitter (Spectramed B.V., Bilthoven, The Netherlands) to measure blood pressure.Using Nihon KohdenCarrier Amplifier (Type AP-621G; Nihon Kohden B.V., Amsterdam, The Netherlands) increase after, go up by Po-Ne-Mah data acquisition program (Po-Ne-Mah Inc., Storrs, USA) recording blood pressure signal at Personal Computer (Compaq Deskpro386s).Heart rate is from the pulsating pressure signal.All compounds are as the fine suspension oral administration in 1% methylcellulose gum, and CB was carried out in induced anesthesia after 30 minutes after 60 minutes
1Receptor stimulant CP-55,940 administrations.Volume injected is 10ml/kg.After the blood dynamic stability, carry out CB
1Receptor stimulant CP-55,940 (0.1mg/kg iv.) administration, and realize blood pressure lowering effect (Wagner, J.A.; Jarai, Z.; Batkai, S.; Kunos, G.Hemodynamic effects of cannabinoids:coronary andcerebral vasodilation mediated by cannabinoid CB1 receptors.Eur J Pharmacol.2001,423,203-210); Lange, J.H.Metal., JMed.Chem.2004,47,627-643.
Cannaboid CB
1(part) agonist activity in the acceptor body
The Cannabined receptor excitement of The compounds of this invention or PAA can for example be intended hemp effective evaluation (J.Pharmacol.Exp.Ther 2001,296 for Wiley, people such as J.L., 1013) and measure according to disclosed method in the body.
Water solubility is measured
These stock solutions are dispensed in several flat boards.Carry out several concentration dilutions with DMSO, reach 5,2.5,1.25,0.625 and 0.3125mg/ml respectively.Take out stock solution and from the various deutero-concentration of stock solution, and water and contain 100 times of the water dilutions of buffer reagent.The aqueous solution that is comprised 1% DMSO (v/v) and 100,50,25,12.5 and 6.25 and 3.125 μ g compound/ml in each case respectively.In each flat board, measure sedimentary formation.Under pH=7, measure, use the HEPBS damping fluid and measure application hydrochloric acid at pH=2.Water solubility is that unit representation is in following table with μ g/ml.
Embodiment 1: particular compound synthetic
Synthesizing of compound 1
Part A: 5-brooethyl-1-(4-chloro-phenyl-)-2-(2,4 dichloro benzene base)-1H-imidazoles-4-ethyl formate
To at CCl
41-(25mL) (4-chloro-phenyl-)-2-(2; the 4-dichlorophenyl)-5-methyl isophthalic acid H-imidazoles-4-ethyl formate (2.05g; 5.00mmol) the magnetic stirred mixture add N-bromosuccinimide (NBS) (1.34g; 7.53mmol) and dibenzoyl superoxide (10.0mg; measured value 75%; 0.0310mmol), and the mixture of gained refluxed 38 hours.Remove by filter the precipitation of formation.Use salt solution and water washing filtrate continuously, use MgSO
4Drying is filtered and vacuum concentration.With flash chromatography (CH
2Cl
2/ acetone=98/2 (v/v)) the purifying resistates obtains 5-brooethyl-1-(4-chloro-phenyl-)-2-(2,4 dichloro benzene base)-1H-imidazoles-4-ethyl formate (1.29g, 53% productive rate), is a kind of amorphous solid,
1H-NMR (200MHz, CDCl
3): δ 1.45 (t, J=7Hz, 3H), 4.48 (q, J=7Hz, 2H), 4.72 (s, 2H), 7.18-7.43 (m, 7H).
Part B: to the 5-brooethyl-1-in acetonitrile (40ml) (4-chloro-phenyl-)-2-(2, the 4-dichlorophenyl)-1H-imidazoles-4-ethyl formate (11.69g, 23.9mmol) the magnetic stirred solution add diisopropyl ethyl amine (DIPEA) (5.2ml, 30mmol) and tetramethyleneimine (1.7g, 23.9mmol), and the solution of gained at room temperature reacted 2 hours.Add entry and with methylene dichloride with the mixture extraction of gained three times.Use Na
2SO
4The dry dichloromethane layer of collecting filters and vacuum concentration.Use flash chromatography (sherwood oil/EtOAc=20/80 (v/v)) purifying to obtain 1-(4-chloro-phenyl-)-2-(2,4-two fluoro-phenyl)-5-(tetramethyleneimine-1-ylmethyl)-1H-imidazoles-4-ethyl formate (3.7 grams, 32% productive rate) then.
1H-NMR(200MHz，CDCl
3)：δ1.42(t，J＝7Hz，3H)，1.62-1.72(m，4H)，2.42-2.50(m，4H)，3.83(s，2H)，4.43(q，J＝7Hz，2H)，7.17-7.40(m，7H)。
Portion C: (0.91ml 8mmol) is dissolved in methylene dichloride (20ml) and adding (CH with cyclo-hexylamine
3)
3Al (solution of 4ml 2M in heptane, 8mmol).The mixture of gained was stirred under room temperature 10 minutes, and (1.8 restrain, 3.8mmol) to add 1-(4-chloro-phenyl-)-2-(2,4 dichloro benzene base)-5-(tetramethyleneimine-1-ylmethyl)-1H-imidazoles-4-ethyl formate.The mixture of gained was stirred under room temperature 16 hours, with its impouring NaHCO
3The aqueous solution stirred 30 minutes and filtered with Hyflo.With methylene dichloride filtrate is washed secondary.Use Na
2SO
4Dry organic layer filters and vacuum concentration.Use flash chromatography (methylene chloride=98/2 (v/v)) purifying to obtain N-cyclohexyl-1-(4-chloro-phenyl-)-2-(2,4 dichloro benzene base)-5-(tetramethyleneimine-1-ylmethyl)-1H-imidazoles-4-methane amide then, compound 1 (1.06 grams; 53% productive rate).Fusing point: 155-157 ℃.
Similarly, the following compound 2-6 of preparation:
2.N-cyclohexyl-1-(4-chloro-phenyl-)-2-(2,4 dichloro benzene base)-5-(N-ethyl, N-methylamino methyl)-1H-imidazoles-4-methane amide.Fusing point: 135-136 ℃.
(3.N-piperidines-1-yl)-1-(4-chloro-phenyl-)-2-(2,4 dichloro benzene base)-5-(N, N-dimethylaminomethyl)-1H-imidazoles-4-methane amide.Fusing point: 163-166 ℃.
4.N-cyclohexyl-1-(4-chloro-phenyl-)-2-(2,4 dichloro benzene base)-5-(N, N-dimethylaminomethyl)-1H-imidazoles-4-methane amide.
1H-NMR(400MHz，CDCl
3)：δ1.12-1.68(m，6H)，1.72-1.80(m，2H)，1.99-2.06(m，2H)，2.18(s，6H)，3.65(s，2H)，3.88-4.00(m，1H)，7.22-7.37(m，8H)。
(5.N-piperidines-1-yl)-1-(4-chloro-phenyl-)-2-(2,4 dichloro benzene base)-5-(tetramethyleneimine-1-ylmethyl)-1H-imidazoles-4-methane amide .2 HCl.
1H-NMR(400MHz，DMSO-d
6)：δ1.46-1.56(m，2H)，1.79-1.96(m，8H)，2.90-3.00(m，2H)，3.26-3.50(m，6H)，4.57(br 5，2H)，7.45-7.60(m，6H)，7.70(d，J＝8Hz，1H)，10.95(brs，2H)。
(6.N-piperidines-1-yl)-1-(4-chloro-phenyl-)-2-(2,4 dichloro benzene base)-5-(N-ethyl, N-methylamino methyl)-1H-imidazoles-4-methane amide.
1H-NMR(400MHz，CDCl
3)：δ0.86(t，J＝7Hz，3H)，1.38-1.46(m，2H)，1.72-1.78(m，4H)，2.14(s，3H)，2.36(q，J＝7Hz，2H)，2.82-2.86(m，4H)，3.72(s，2H)，7.21-7.31(m，6H)，7.34(d，J＝2Hz，1H)，8.16(brs，1H)。
Embodiment 2: the mensuration of water solubility
Measure the compound of two kinds of general formulas (I) according to above-mentioned method, compound 1 and 4 and the water solubility of compound 1-(4-chloro-phenyl-)-2-(2,4-two chloro-phenyl)-N-cyclohexyl-1H-imidazoles-4-methane amide (from the compound 3 of WO03/063781).The result is as shown in table 1.
Table 1: water solubility (representing) with μ g/ml
Embodiment 3: pharmacology data
The pharmacology test result of the one group of The compounds of this invention that obtains with above-mentioned test provides in following table 2:
Table 2: pharmacology data
| People's cannaboid CB 1Acceptor | |
| External avidity-pK iValue | |
| Compound | |
| Compound 1 | 8.1 |
| Compound 2 | 8.2 |
| Compound 3 | 7.0 |
| Compound 4 | 7.5 |
| Compound 5 | 6.3 |
| Compound 6 | 6.9 |
Claims (10)
1. general formula (I
*) compound, or its all steric isomer, or acceptable salt on its pharmacology:
Wherein:
-R and R
1Identical or different; represent phenyl; it is not substituted or is replaced by 1 or 2 substituting group Y; substituting group Y is identical or different; be selected from methyl, ethyl, propyl group, methoxyl group, oxyethyl group, hydroxyl, hydroxymethyl, hydroxyethyl, chlorine, iodine, bromine, fluorine, trifluoromethyl, trifluoromethoxy, methyl sulphonyl, phenyl and cyano group
-R
2And R
3Identical or different, and represent H, C
1-5Branched-chain or straight-chain alkyl, perhaps
R
2And R
3With form the monocyclic heterocyclic group of saturated or unsaturated non-fragrance with 5-10 annular atoms with their bonded nitrogen-atoms,
-R
6Represent hydrogen atom or side chain or straight chain C
1-3Alkyl,
-R
7Represent hydrogen atom, side chain or straight chain C
1-8Alkyl, C
3-8Cycloalkyl, described group do not contain heteroatoms or comprise a N atom.
2. general formula (the I of claim 1
*) compound, or its all steric isomer, or acceptable salt on its pharmacology,
Wherein:
-R, R
1And R
6Definition with claim 1,
-R
2And R
3Identical or different, and represent H, C
1-5Branched-chain or straight-chain alkyl, perhaps
-R
2And R
3With form pyrrolidyl with their bonded nitrogen-atoms,
-R
7Represent hydrogen atom, side chain or straight chain C
1-8Alkyl, cyclohexyl or piperidines-1-base.
3. the compound of claim 1, or its all steric isomer, or acceptable salt on its pharmacology are selected from:
N-cyclohexyl-1-(4-chloro-phenyl-)-2-(2,4 dichloro benzene base)-5-(tetramethyleneimine-1-ylmethyl)-1H-imidazoles-4-methane amide;
N-cyclohexyl-1-(4-chloro-phenyl-)-2-(2,4 dichloro benzene base)-5-(N-ethyl, N-methylamino methyl)-1H-imidazoles-4-methane amide;
N-(piperidines-1-yl)-1-(4-chloro-phenyl-)-2-(2,4 dichloro benzene base)-5-(N, N-dimethylaminomethyl)-1H-imidazoles-4-methane amide;
N-cyclohexyl-1-(4-chloro-phenyl-)-2-(2,4 dichloro benzene base)-5-(N, N-dimethylaminomethyl)-1H-imidazoles-4-methane amide;
N-(piperidines-1-yl)-1-(4-chloro-phenyl-)-2-(2,4 dichloro benzene base)-5-(tetramethyleneimine-1-ylmethyl)-1H-imidazoles-4-methane amide; With
N-(piperidines-1-yl)-1-(4-chloro-phenyl-)-2-(2,4 dichloro benzene base)-5-(N-ethyl, N-methylamino methyl)-1H-imidazoles-4-methane amide.
4. the compound of general formula (IV)
Wherein R, R
1, R
2And R
3Have the implication that claim 1 provides, and R
10Represent hydrogen atom, straight or branched C
1-4Alkyl or benzyl, these compounds can be used for synthetic general formula (I shown in claim 1
*) compound, R wherein, R
1, R
2, R
3, R
6And R
7Definition with claim 1.
5. comprise at least a each desired compound, or its all steric isomer as claim 1-3, or on its pharmacology acceptable salt as the pharmaceutical composition of active ingredient.
6. the desired compound of each of claim 1-3, or its all steric isomer, or the application that acceptable salt is used to prepare the pharmaceutical composition for the treatment of the disease that relates to the cannaboid neurotransmission on its pharmacology.
7. claim 6 desired application, wherein said disease are selected from psychosis, anxiety, depression, obesity, habituation, desire, drug dependence, dementia, muscle rigidity, tremble, epilepsy, multiple sclerosis, traumatic brain injury, apoplexy, Parkinson's disease, Alzheimer, Huntington, Tourette's syndrome, cerebral ischemia, Spinal injury, spot sclerosis, viral encephalitis, pain disease, septic shock, glaucoma, cancer, diabetes, vomiting, feel sick, asthma, liver cirrhosis, stomach ulcer and diarrhoea.
8. claim 7 desired application, wherein said obesity are the fat or drug-induced obesity of teenager.
9. as the desired compound of claim 1, or its all steric isomer, or the application that acceptable salt is used to prepare the fat pharmaceutical composition of treatment on its pharmacology, it is characterized in that described pharmaceutical composition also comprises at least a lipase inhibitor.
10. as claim 9 desired application, wherein said lipase inhibitor is orlistat or mud pool Si Tating.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03103867 | 2003-10-20 | ||
| EP03103867.2 | 2003-10-20 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1842520A CN1842520A (en) | 2006-10-04 |
| CN100556894C true CN100556894C (en) | 2009-11-04 |
Family
ID=34924117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004800243493A Expired - Fee Related CN100556894C (en) | 2003-10-20 | 2004-10-19 | 1H-imdazole derivatives as Cannibinoid receptor modulators |
Country Status (7)
| Country | Link |
|---|---|
| CN (1) | CN100556894C (en) |
| AR (1) | AR046182A1 (en) |
| HK (1) | HK1091823A1 (en) |
| SA (1) | SA04250339B1 (en) |
| TW (1) | TW200524908A (en) |
| UA (1) | UA82908C2 (en) |
| ZA (1) | ZA200603124B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101302200B (en) * | 2007-05-09 | 2011-04-20 | 上海医药工业研究院 | Preparation of N-piperidine subbase-5-(4-chlorphenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-formamide |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003027076A2 (en) * | 2001-09-21 | 2003-04-03 | Solvay Pharmaceuticals B.V. | 1h-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1- antagonistic activity |
| WO2003063781A2 (en) * | 2002-01-29 | 2003-08-07 | Merck & Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
-
2004
- 2004-10-15 AR ARP040103749 patent/AR046182A1/en not_active Application Discontinuation
- 2004-10-15 TW TW93131338A patent/TW200524908A/en unknown
- 2004-10-17 SA SA4250339A patent/SA04250339B1/en unknown
- 2004-10-19 CN CNB2004800243493A patent/CN100556894C/en not_active Expired - Fee Related
- 2004-10-19 UA UAA200605398A patent/UA82908C2/en unknown
-
2006
- 2006-04-19 ZA ZA200603124A patent/ZA200603124B/en unknown
- 2006-11-09 HK HK06112346.0A patent/HK1091823A1/en not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003027076A2 (en) * | 2001-09-21 | 2003-04-03 | Solvay Pharmaceuticals B.V. | 1h-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1- antagonistic activity |
| WO2003063781A2 (en) * | 2002-01-29 | 2003-08-07 | Merck & Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
Also Published As
| Publication number | Publication date |
|---|---|
| UA82908C2 (en) | 2008-05-26 |
| SA04250339B1 (en) | 2008-07-19 |
| AR046182A1 (en) | 2005-11-30 |
| CN1842520A (en) | 2006-10-04 |
| HK1091823A1 (en) | 2007-01-26 |
| TW200524908A (en) | 2005-08-01 |
| ZA200603124B (en) | 2007-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4693787B2 (en) | 1,3,5-trisubstituted 4,5-dihydro-1H-pyrazole derivatives having CB1 antagonistic activity | |
| US7109216B2 (en) | 1H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity | |
| AU2005214084B2 (en) | Imidazoline derivatives having CB1-antagonistic activity | |
| US7745476B2 (en) | 1,3,5-trisubstituted 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity | |
| ZA200402188B (en) | 1H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity. | |
| IL173436A (en) | 1h-imidazole derivatives, intermediates thereof, pharmaceutical compositions comprising them and their use as cannabinoid receptor modulators | |
| CN100556894C (en) | 1H-imdazole derivatives as Cannibinoid receptor modulators | |
| US7524867B2 (en) | Tetrasubstituted imidazole derivatives as cannabinoid CB1 receptor modulators with a high CB1/CB2 receptor subtype selectivity | |
| US7498348B2 (en) | 1 H-imidazole derivatives as cannabinoid receptor modulators | |
| JP2008500994A (en) | Tetrasubstituted imidazole derivatives as cannabinoid CB1 receptor modulators with high CB1 / CB2 receptor subtype selectivity | |
| US7173044B2 (en) | Imidazoline derivatives having CB1-antagonistic activity | |
| JP2011518800A (en) | (5R) -1,5-diaryl-4,5-dihydro-1H-pyrazole-3-carboxyamidine derivatives having CB1 antagonist activity | |
| CN101823999A (en) | 1,3,5-trisubstituted 4,5 - dihydro - 1H - pyrazole derivatives having CB1 - antagonistic activity | |
| CN101076520B (en) | Imidazoline derivatives having cb1-antagonistic activity | |
| CN1956965B (en) | Tetrasubstituted imidazole derivatives as cannabinoid cb1 receptor modulators with a high CB1/CB2 receptor subtype selectivity | |
| MXPA06009508A (en) | Imidazoline derivatives having cb1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1091823 Country of ref document: HK |
|
| CI01 | Correction of invention patent gazette |
Correction item: Third inventor Correct: Van Stuivenberg Herman H. False: Stuivenberg Herman H. Number: 40 Volume: 22 |
|
| CI02 | Correction of invention patent application |
Correction item: Third inventor Correct: Van Stuivenberg Herman H. False: Stuivenberg Herman H. Number: 40 Page: The title page Volume: 22 |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: THE THIRD INVENTOR; FROM: STUIVENBERG HERMAN H. TO: VAN STUIVENBERG HERMAN H. |
|
| ERR | Gazette correction |
Free format text: CORRECT: THE THIRD INVENTOR; FROM: STUIVENBERG HERMAN H. TO: VAN STUIVENBERG HERMAN H. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1091823 Country of ref document: HK |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20091104 Termination date: 20111019 |